Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
The HELIOS-B trial showed vutrisiran improves survival and cardiac outcomes in transthyretin amyloidosis with cardiomyopathy, with consistent benefits regardless of baseline tafamidis use, supporting further evaluation of combination therap
Vutrisiran, an RNA interference therapeutic, significantly improves cardiac function, reduces amyloid burden, and attenuates disease progression in transthyretin amyloid cardiomyopathy as revealed by multiparametric cardiovascular MRI and c
In Medicare beneficiaries, ATTR-CM was diagnosed a median 494 days after heart failure and 840 days after loop diuretic initiation, with delays more common in women and patients with several common comorbidities.
This review synthesizes the 54-month results of the ATTRibute-CM open-label extension, demonstrating that early and continuous acoramidis treatment provides sustained reductions in mortality and cardiovascular hospitalizations while maintai
This review synthesizes recent evidence identifying MR-proADM as a premier prognostic biomarker in ATTR-CM, demonstrating its ability to outperform traditional natriuretic peptides and enhance existing clinical staging systems.
The HELIOS-B trial demonstrates that vutrisiran significantly improves clinical outcomes, stabilizes cardiac biomarkers, preserves cardiac structure, and enhances the quality of life in patients with transthyretin amyloidosis with cardiomyo
A Phase 2 randomized trial shows that coramitug, a monoclonal antibody targeting misfolded transthyretin, significantly reduced NT-proBNP levels by 48% in patients with ATTR-CM. While functional outcomes remained stable over 52 weeks, the r
An AI-driven screening program (ATTRACTnet) applied to ECG, echocardiography, demographics and orthopedic history substantially increased case detection of transthyretin cardiac amyloidosis (ATTR‑CM) and led to rapid treatment initiation in
Vutrisiran improves cardiac structure, function, and biomarkers, reducing mortality and cardiovascular events in transthyretin amyloid cardiomyopathy over 30 months.